Viracta Therapeutics (VIRX) Short Interest Ratio & Short Volume $0.02 0.00 (-0.79%) As of 03:50 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Viracta Therapeutics Short Interest DataViracta Therapeutics (VIRX) has a short interest of 184,200 shares, representing 0.66% of the float (the number of shares available for trading by the public). This marks a -25.12% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.1, indicating that it would take 0.1 days of the average trading volume of 1.07 million shares to cover all short positions.Current Short Interest184,200 sharesPrevious Short Interest246,000 sharesChange Vs. Previous Month-25.12%Dollar Volume Sold Short$27,906.30Short Interest Ratio0.1 Days to CoverLast Record DateJanuary 31, 2025Outstanding Shares39,744,000 sharesFloat Size28,010,000 sharesShort Percent of Float0.66%Today's Trading Volume100,016 sharesAverage Trading Volume1,074,513 sharesToday's Volume Vs. Average9% Short Selling Viracta Therapeutics? Sign up to receive the latest short interest report for Viracta Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartVIRX Short Interest Over TimeVIRX Days to Cover Over TimeVIRX Percentage of Float Shorted Over Time Remove Ads Viracta Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/31/2025184,200 shares $27,906.30 -25.1%0.7%0.1 $0.15 1/15/2025246,000 shares $40,344.00 -59.7%0.9%0.1 $0.16 12/31/2024609,900 shares $98,132.91 -79.7%2.2%0.2 $0.16 12/15/20243,000,000 shares $608,100.00 +89.9%10.7%1.4 $0.20 11/30/20241,580,000 shares $221,200.00 -24.8%5.7%0.8 $0.14 11/15/20242,100,000 shares $317,100.00 -21.9%7.5%2 $0.15 10/31/20242,690,000 shares $542,842.00 +144.6%9.7%1.9 $0.20 10/15/20241,100,000 shares $241,560.00 -17.3%4.0%1.7 $0.22 9/30/20241,330,000 shares $307,762.00 +1.5%4.8%2.1 $0.23 9/15/20241,310,000 shares $328,810.00 +4.0%4.7%2.1 $0.25 Get the Latest News and Ratings for VIRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/20241,260,000 shares $269,136.00 -50.4%4.6%2.1 $0.21 8/15/20242,540,000 shares $885,190.00 +178.5%9.2%4.8 $0.35 7/31/2024912,000 shares $436,848.00 -6.4%3.3%8.5 $0.48 7/15/2024974,800 shares $517,618.80 +35.2%3.5%10.7 $0.53 6/30/2024721,000 shares $392,007.70 +1.7%2.6%7 $0.54 6/15/2024708,900 shares $477,656.82 +3.8%2.6%6.7 $0.67 5/31/2024682,700 shares $477,890.00 +2.1%2.5%6.3 $0.70 5/15/2024668,400 shares $561,456.00 -4.4%2.4%6.5 $0.84 4/30/2024699,400 shares $573,228.24 +1.9%2.5%6.3 $0.82 4/15/2024686,700 shares $535,626.00 +6.0%2.5%6.2 $0.78 3/31/2024648,000 shares $660,960.00 +2.2%2.4%6.8 $1.02 3/15/2024634,300 shares $631,762.80 -7.1%2.3%5.7 $1.00 2/29/2024683,000 shares $556,645.00 +0.6%2.5%5 $0.82 2/15/2024678,800 shares $433,753.20 +4.5%2.5%4.5 $0.64 1/31/2024649,900 shares $370,443.00 +0.4%2.4%4 $0.57 1/15/2024647,500 shares $384,226.50 -1.9%2.4%3.8 $0.59 12/31/2023660,300 shares $376,371.00 -14.9%2.5%3.8 $0.57 12/15/2023776,100 shares $361,973.04 +19.3%2.9%4.6 $0.47 11/30/2023650,700 shares $316,890.90 -8.2%2.4%4.9 $0.49 11/15/2023708,700 shares $425,503.48 +3.0%2.6%7.3 $0.60 10/31/2023688,200 shares $424,275.30 +12.0%2.6%7.5 $0.62 10/15/2023614,700 shares $436,437.00 -2.7%2.3%7.6 $0.71 9/30/2023632,000 shares $657,280.00 -4.3%2.4%7 $1.04 9/15/2023660,200 shares $838,454.00 -5.3%2.5%7.8 $1.27 8/31/2023697,200 shares $1.00 million -4.4%2.6%6.8 $1.44 8/15/2023729,100 shares $947,830.00 +5.2%2.7%4.5 $1.30 7/31/2023692,900 shares $1.07 million -3.9%2.6%2.8 $1.55 7/15/2023721,000 shares $1.05 million -1.0%2.7%2.9 $1.45 6/30/2023728,500 shares $1.03 million -7.8%2.8%3 $1.41 6/15/2023789,900 shares $1.26 million +14.0%3.0%3.3 $1.59Trump’s Great Society (Ad)Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.Millions of Americans are about to be wiped out, while others could make a fortune… click here to ma 5/31/2023693,200 shares $921,956.00 +12.4%2.6%3.2 $1.33 5/15/2023616,700 shares $807,877.00 -2.2%2.3%3.4 $1.31 4/30/2023630,800 shares $813,732.00 +2.0%2.4%8.4 $1.29 4/15/2023618,300 shares $902,718.00 -2.5%2.3%9.6 $1.46 3/31/2023634,000 shares $1.01 million -19.5%2.4%8.4 $1.59 3/15/2023787,800 shares $1.33 million +51.7%3.0%8.7 $1.69 2/28/2023519,200 shares $882,640.00 +3.9%2.0%4.9 $1.70 2/15/2023499,500 shares $994,005.00 +5.6%1.9%4.5 $1.99 1/31/2023473,000 shares $983,840.00 -2.5%1.8%3.8 $2.08 1/15/2023485,300 shares $1.10 million +3.2%1.8%3.9 $2.26 12/30/2022470,300 shares $686,638.00 -15.1%1.8%3.8 $1.46 12/15/2022553,600 shares $1.06 million -0.1%2.1%5.2 $1.92 11/30/2022553,900 shares $1.29 million +7.3%2.1%5.1 $2.32 11/15/2022516,200 shares $1.50 million +8.8%2.0%4.8 $2.90 10/31/2022474,600 shares $1.87 million -9.6%1.9%4.7 $3.93 10/15/2022525,100 shares $1.97 million -4.4%2.0%5.1 $3.75 9/30/2022549,000 shares $2.34 million +9.3%2.1%5 $4.27 9/15/2022502,100 shares $2.81 million -3.9%2.0%2.6 $5.59 8/31/2022522,300 shares $2.12 million +0.6%2.0%2.3 $4.05 8/15/2022519,100 shares $2.29 million -8.2%2.0%2.2 $4.42 7/31/2022565,400 shares $1.88 million -16.1%1.9%2.2 $3.32 7/15/2022673,800 shares $2.99 million -32.5%2.3%2.5 $4.44 6/30/2022998,500 shares $3.87 million -48.5%3.4%3.2 $3.88 6/15/20221,940,000 shares $4.85 million -3.0%6.5%6.1 $2.50 5/31/20222,000,000 shares $4.24 million +8.7%6.7%8.1 $2.12 5/15/20221,840,000 shares $3.44 million -7.1%6.2%7.3 $1.87 4/30/20221,980,000 shares $5.05 million +16.5%6.7%6.2 $2.55 4/15/20221,700,000 shares $6.90 million +20.6%5.7%5.2 $4.06 3/31/20221,410,000 shares $6.71 million +20.5%4.8%4.7 $4.76 3/15/20221,170,000 shares $2.61 million +13.6%3.9%4.2 $2.23 2/28/20221,030,000 shares $2.81 million +7.8%3.5%3.5 $2.73 2/15/2022955,900 shares $2.98 million +26.0%3.2%3 $3.12 1/31/2022758,800 shares $2.03 million +5.5%2.7%2.9 $2.68 1/15/2022719,100 shares $2.28 million -15.4%2.5%3.3 $3.17 12/31/2021849,800 shares $3.10 million -2.7%3.0%3.7 $3.65 12/15/2021873,100 shares $3.12 million +30.4%3.1%4 $3.57 11/30/2021669,400 shares $3.09 million -24.3%2.4%3.8 $4.61 11/15/2021884,500 shares $4.93 million -15.0%3.1%5.5 $5.57 10/29/20211,040,000 shares $6.12 million -7.1%3.5%6.6 $5.88 10/15/20211,120,000 shares $7.25 million -1.8%3.8%7.5 $6.47 9/30/20211,140,000 shares $9.14 million -5.0%3.8%8.5 $8.02 9/15/20211,200,000 shares $10.08 million -9.1%4.0%5.5 $8.40 8/31/20211,320,000 shares $12.17 million -15.9%4.4%4.9 $9.22 8/13/20211,570,000 shares $16.11 million No Change5.3%5.7 $10.26 VIRX Short Interest - Frequently Asked Questions What is Viracta Therapeutics' current short interest? Short interest is the volume of Viracta Therapeutics shares that have been sold short but have not yet been covered or closed out. As of January 31st, traders have sold 184,200 shares of VIRX short. 0.66% of Viracta Therapeutics' shares are currently sold short. Learn More on Viracta Therapeutics' current short interest. Which institutional investors are shorting Viracta Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Viracta Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Viracta Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.66% of Viracta Therapeutics' floating shares are currently sold short. Is Viracta Therapeutics' short interest increasing or decreasing? Viracta Therapeutics saw a decrease in short interest in January. As of January 31st, there was short interest totaling 184,200 shares, a decrease of 25.1% from the previous total of 246,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Viracta Therapeutics' float size? Viracta Therapeutics currently has issued a total of 39,744,000 shares. Some of Viracta Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Viracta Therapeutics currently has a public float of 28,010,000 shares. How does Viracta Therapeutics' short interest compare to its competitors? 0.66% of Viracta Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Viracta Therapeutics: Synaptogenix, Inc. (1.45%), Purple Biotech Ltd (1.94%), CNS Pharmaceuticals, Inc. (6.17%), Upexi, Inc. (3.82%), Titan Pharmaceuticals, Inc. (1.47%), Genprex, Inc. (4.03%), 180 Life Sciences Corp. (4.06%), Genetic Technologies Limited (0.59%), InMed Pharmaceuticals Inc. (3.05%), Artelo Biosciences, Inc. (0.04%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short Viracta Therapeutics stock? Short selling VIRX is an investing strategy that aims to generate trading profit from Viracta Therapeutics as its price is falling. VIRX shares are trading down $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Viracta Therapeutics? A short squeeze for Viracta Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of VIRX, which in turn drives the price of the stock up even further. How often is Viracta Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VIRX, twice per month. The most recent reporting period available is January, 31 2025. More Short Interest Resources from MarketBeat Related Companies SNPX Short Squeeze PPBT Short Squeeze CNSP Short Squeeze UPXI Short Squeeze TTNP Short Squeeze GNPX Short Squeeze ATNF Short Squeeze GENE Short Squeeze INM Short Squeeze ARTL Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VIRX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VIRX Stock Free VIRX Stock Alerts